trans-sodium-crocetinate and Coronary-Disease

trans-sodium-crocetinate has been researched along with Coronary-Disease* in 1 studies

Trials

1 trial(s) available for trans-sodium-crocetinate and Coronary-Disease

Article	Year
The effect of crocetin supplementation on markers of atherogenic risk in patients with coronary artery disease: a pilot, randomized, double-blind, placebo-controlled clinical trial. Food & function, 2019, Nov-01, Volume: 10, Issue:11 Molecular mechanisms of atherogenesis are considered to be emerging therapeutic targets for atherosclerosis prevention. Cell and animal studies have shown that crocetin can decelerate atherogenesis. However, the anti-atherogenic properties of crocetin in humans are still ambiguous.. Fifty clinically diagnosed CAD patients were randomly divided into two parallel groups, crocetin and placebo, who received one capsule of crocetin (10 mg) and placebo per day, respectively, for two months. Serum circulating homocysteine (Hcy) [-1.09 (-1.64 to -0.54) μM, P = 0.001], heart-type fatty acid binding protein (h-FABP) [-2.07 (-2.72 to -1.43) ng mL. As the first human study, we showed the ability of crocetin to alter the expression of atherogenic genes and endothelial cell adhesion molecules in CAD patients. It appears that crocetin could be considered as a promising anti-atherogenic candidate for future studies. Topics: Atherosclerosis; Biomarkers; Carotenoids; Coronary Disease; Dietary Supplements; Double-Blind Method; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Pilot Projects; Risk Factors; Vitamin A	2019

Article

Year

The effect of crocetin supplementation on markers of atherogenic risk in patients with coronary artery disease: a pilot, randomized, double-blind, placebo-controlled clinical trial.

Food & function, 2019, Nov-01, Volume: 10, Issue:11

Molecular mechanisms of atherogenesis are considered to be emerging therapeutic targets for atherosclerosis prevention. Cell and animal studies have shown that crocetin can decelerate atherogenesis. However, the anti-atherogenic properties of crocetin in humans are still ambiguous.. Fifty clinically diagnosed CAD patients were randomly divided into two parallel groups, crocetin and placebo, who received one capsule of crocetin (10 mg) and placebo per day, respectively, for two months. Serum circulating homocysteine (Hcy) [-1.09 (-1.64 to -0.54) μM, P = 0.001], heart-type fatty acid binding protein (h-FABP) [-2.07 (-2.72 to -1.43) ng mL. As the first human study, we showed the ability of crocetin to alter the expression of atherogenic genes and endothelial cell adhesion molecules in CAD patients. It appears that crocetin could be considered as a promising anti-atherogenic candidate for future studies.

Topics: Atherosclerosis; Biomarkers; Carotenoids; Coronary Disease; Dietary Supplements; Double-Blind Method; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Pilot Projects; Risk Factors; Vitamin A

2019